LGALS9 and familial pancreatic carcinoma: Similarly, to avoid the limitations of a single predictor, galectin-9 was included in a compelling immune biomarker panel to predict cancer-specific survival in pancreatic cancer, which might also benefit future prospective immunotherapy trials [28].